关于召开 2025 年半年度业绩说明会的公告 证券代码：688236 证券简称：春立医疗 公告编号：2025-034 北京市春立正达医疗器械股份有限公司 （一） 会议召开时间：2025 年 9 月 1 日上午 10:00-11:00 （二） 会议召开地点：上证路演中心（https://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 8 月 25 日（星期一）至 8 月 29 日（星期五）16:00 前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@clzd.com 进行提问。公司 将在说明会上对投资者普遍关注的问题进行回答。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）将于 2025 年 8 月 30 日 发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经 营成果、财务状况，公司计划于 2025 年 9 月 ...

Group 1 - The core viewpoint of the article highlights the recent stock performance of Spring Medical, which has seen a year-to-date increase of 77.40%, but a decline of 4.84% over the last five trading days [2][3] - As of August 22, Spring Medical's stock price was reported at 22.62 yuan per share, with a market capitalization of 8.676 billion yuan [1] - The company primarily engages in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] Group 2 - Spring Medical's revenue for the first quarter of 2025 reached 230 million yuan, reflecting a year-on-year growth of 3.60%, while the net profit attributable to shareholders was 58.071 million yuan, up 5.20% year-on-year [3] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [4] - As of March 31, 2025, the number of shareholders increased by 7.48% to 7,182, while the average circulating shares per person decreased by 6.99% to 11,063 shares [3]

Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Spring Medical, indicating a significant net buying in the financing market on August 20, with a net purchase amount of 4.17 million yuan [1] - On August 20, Spring Medical's financing buy amounted to 12.64 million yuan, with a total financing balance of 47.98 million yuan, representing 0.71% of its market capitalization, which is above the 90th percentile of the past year [1] - The company has not engaged in any short selling activities on August 20, with no shares sold or repaid, indicating a stable position in the short selling market [1] Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - As of March 31, Spring Medical reported a revenue of 230 million yuan for the first quarter of 2025, reflecting a year-on-year growth of 3.6%, and a net profit attributable to shareholders of 58.07 million yuan, up 5.2% year-on-year [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] Group 3 - As of March 31, 2025, the number of shareholders in Spring Medical increased by 7.48% to 7,182, while the average circulating shares per person decreased by 6.99% to 11,063 shares [2] - Among the top ten circulating shareholders, Zhonggeng Small Cap Value Stock holds 2.87 million shares, remaining unchanged, while Hong Kong Central Clearing Limited increased its holdings by 1.11 million shares to 2.29 million shares [3] - New shareholders include Ping An Low Carbon Economy Mixed A, which holds 1 million shares, while some funds exited the top ten circulating shareholders list [3]

Core Viewpoint - The stock of Chunli Medical (688236) has shown a slight increase, with a closing price of 23.29 yuan on August 20, 2025, reflecting a 1.57% rise, amidst mixed capital flows from different investor categories [1][2]. Group 1: Stock Performance and Capital Flow - On August 20, 2025, Chunli Medical's stock recorded a trading volume of 33,100 hands and a total transaction amount of 76.81 million yuan [1]. - The net inflow of main funds was 2.3652 million yuan, accounting for 3.08% of the total transaction amount, while retail investors experienced a net outflow of 3.998 million yuan, representing 5.20% of the total [1][2]. - Over the past five days, the stock has seen fluctuations in capital flow, with the highest net inflow of main funds recorded on August 19 at 2.5814 million yuan, and the largest net outflow of retail funds on August 14 at 7.4103 million yuan [2]. Group 2: Financial Metrics and Industry Comparison - Chunli Medical's total market value is 8.933 billion yuan, which is below the industry average of 12.109 billion yuan, ranking 43rd out of 123 companies in the medical device sector [3]. - The company reported a net profit of 58.0711 million yuan for Q1 2025, reflecting a year-on-year increase of 5.2%, with a gross margin of 66.69%, significantly higher than the industry average of 51.29% [3]. - The company's return on equity (ROE) stands at 2.04%, outperforming the industry average of 1.28%, indicating a relatively efficient use of equity capital [3]. Group 3: Analyst Ratings - In the last 90 days, three institutions have provided ratings for Chunli Medical, all of which are buy ratings, indicating a positive outlook from analysts [4].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Spring Medical, which has a current stock price of 23.29 yuan, a PE ratio of 69.87, and a total market capitalization of 8.933 billion yuan [1][2] - The average PE ratio for the medical device industry is 59.32, with a median of 39.97, positioning Spring Medical at the 93rd rank within the industry [1][2] - As of March 31, 2025, Spring Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.071 million yuan, reflecting a year-on-year increase of 5.20%, with a gross margin of 66.69% [1]

Group 1 - The core viewpoint of the article highlights that Spring Medical's stock closed at 22.93 yuan, down 2.76%, with a rolling PE ratio of 68.79 times and a total market value of 8.795 billion yuan [1] - The average PE ratio for the medical device industry is 59.49 times, with a median of 40.19 times, placing Spring Medical at the 91st position in the industry ranking [1] - As of March 31, 2025, Spring Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, PRP preparation kits, and negative pressure wound drainage kits [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - In the latest quarterly report for Q1 2025, Spring Medical achieved an operating income of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.071 million yuan, a year-on-year increase of 5.20%, with a gross profit margin of 66.69% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 董事會會議通告 北京市春立正達醫療器械股份有限公司（「本公司」）之董事會（「董事會」）謹此 宣佈將於2025年8月29日（星期五）舉行董事會會議，藉以（其中包括）批准本公 司及其附屬公司截至2025年6月30日止六個月之中期業績公佈及考慮派付中期 股息（如有）。 代表董事會 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國，北京，2025年8月19日 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 截至本公告日期，執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；非執行 董事為王鑫先生；及獨立非執行董事為徐泓女士、黃德盛先生及翁杰先生。 * 僅供識別 ...

Core Viewpoint - Spring Medical (01858.HK) announced a board meeting scheduled for August 29, 2025, to approve the interim results for the six months ending June 30, 2025, and to consider the payment of an interim dividend, if any [1] Group 1 - The board meeting will take place on a Friday [1] - The interim results will cover the period ending June 30, 2025 [1] - The consideration of an interim dividend is included in the agenda [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* * 僅供識別 代表董事會 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國，北京，2025年8月19日 截至本公告日期，執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；非執行 董事為王鑫先生；及獨立非執行董事為徐泓女士、黃德盛先生及翁杰先生。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 董事會會議通告 北京市春立正達醫療器械股份有限公司（「本公司」）之董事會（「董事會」）謹此 宣佈將於2025年8月29日（星期五）舉行董事會會議，藉以（其中包括）批准本公 司及其附屬公司截至2025年6月30日止六個月之中期業績公佈及考慮派付中期 股息（如有）。 ...

Group 1 - The core viewpoint of the news is that Spring Medical has shown significant stock performance, with an 88.85% increase in stock price year-to-date, despite a recent decline of 3.99% over the last five trading days [1] - As of August 19, the stock price of Spring Medical is 24.08 CNY per share, with a market capitalization of 9.236 billion CNY and a trading volume of 13.42 million CNY [1] - The company primarily engages in the research, production, and sales of orthopedic medical devices, focusing on joint prosthetics and spinal implants, with 99.92% of its revenue coming from medical device products [1][2] Group 2 - As of March 31, the company reported a revenue of 230 million CNY for Q1 2025, representing a year-on-year growth of 3.60%, and a net profit of 58.07 million CNY, which is a 5.20% increase compared to the previous year [2] - The company has distributed a total of 359 million CNY in dividends since its A-share listing, with 309 million CNY distributed over the past three years [3] - The number of shareholders increased by 7.48% to 7,182 as of March 31, while the average number of circulating shares per person decreased by 6.99% to 11,063 shares [2]